The Lead Episode 177: A Discussion of the PIFPAF-PFA Randomized Clinical Trial
Availability
On-Demand
Expires on Nov 09, 2029
Cost
$0.00
Credit Offered
No Credit Offered

In this episode of The Lead, recorded live at HRX 2026, host Jason T. Jacobson, MD, FHRS, of Westchester Medical Center–New York Medical College, is joined by Jason G. Andrade, MD, FHRS, of Vancouver General Hospital, and Jason D. Roberts, MD, of McMaster University, to discuss the recently published JAMA article “Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF Randomized Clinical Trial.” The panel examines the trial's findings, including the lack of a statistically significant reduction in its primary endpoint, potential benefits in reducing atrial fibrillation burden and longer-duration recurrences, and the implications of trial design, outcome definitions, and patient selection for clinical practice.

  1. Describe the design, patient population, and primary and secondary outcomes of the PIFPAF trial comparing pulmonary vein isolation alone with additional posterior wall isolation using pulsed field ablation in patients with persistent atrial fibrillation.

  2. Evaluate the clinical significance of atrial fibrillation recurrence duration and burden as measures of ablation success, including the limitations of a 30-second recurrence threshold.

  3. Assess the potential benefits and limitations of posterior wall isolation using pulsed field ablation and its implications for selecting appropriate patients with persistent atrial fibrillation.


Podcast Contributors

Host: 

Jason T. Jacobson, MD, FHRS | Westchester Med Center-New York Medical College

 

Guests: 

Jason G. Andrade, MD, FHRS | Vancouver General Hospital

Jason D. Roberts, MD | McMaster University

 

 

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

J. Jacobson
  • Honoraria/Speaking/Consulting Fee: Zoll Medical Corporation, Vektor Medical, Inc., CardioFocus, Inc., Abbott Medical, Johnson and Johnson
  • Stock Options-Privately Held: Atlas 5D


J. Andrade

  • Nothing to disclose


J. Roberts

  • Intellectual Property Rights: Venca Research




Staff Disclosu
re(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.
M. Baldwin: No relevant financial relationships with ineligible companies to disclose.